

# John B Patterson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3770280/publications.pdf>

Version: 2024-02-01

9  
papers

1,382  
citations

1040056

9  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

2091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blockade of XBP1 splicing by inhibition of IRE1 <sup>±</sup> is a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012, 119, 5772-5781.	1.4	353
2	Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. <i>Nature Communications</i> , 2018, 9, 3267.	12.8	192
3	Potent and Selective Inhibitors of the Inositol-requiring Enzyme 1 Endoribonuclease. <i>Journal of Biological Chemistry</i> , 2011, 286, 12743-12755.	3.4	190
4	Pharmacological targeting of the unfolded protein response for disease intervention. <i>Nature Chemical Biology</i> , 2019, 15, 764-775.	8.0	188
5	Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1283-1299.	8.2	163
6	IRE1 <sup>±</sup> -XBP1s pathway promotes prostate cancer by activating c-MYC signaling. <i>Nature Communications</i> , 2019, 10, 323.	12.8	158
7	Structure and mechanism of action of the hydroxy-aryl aldehyde class of IRE1 endoribonuclease inhibitors. <i>Nature Communications</i> , 2014, 5, 4202.	12.8	108
8	Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia. <i>Oncotarget</i> , 2018, 9, 2984-3000.	1.8	15
9	The IRE1 and PERK arms of the unfolded protein response promote survival of rhabdomyosarcoma cells. <i>Cancer Letters</i> , 2020, 490, 76-88.	7.2	11